Atlas Trials

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Clinical trial NCT05007613 · COMPLETED

Trial details

NCT number
NCT05007613
Sponsor
National Taiwan University Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal CancerMetastatic CancerSquamous Cell Carcinoma
Start date
2021-06-23
Primary completion
2024-07-17
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.